Summit Therapeutics signs up to $5 bln licensing deal for experimental cancer therapy
06/12/2022 12:42
Dec 6 (Reuters) - Summit Therapeutics Inc SMMT.O said
on Tuesday it has signed a licensing deal worth up to $5 billion
with China-based Akeso Inc 9926.HK for an experimental cancer
therapy.
Summit said it would make an upfront payment of $500
million, and Akeso will be eligible for regulatory and
commercial milestone payments of up to $4.5 billion.
(Reporting by Leroy Leo in Bengaluru;
Editing by Vinay Dwivedi)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals